Last C$5.70 CAD
Change Today -0.03 / -0.52%
Volume 8.3K
RX On Other Exchanges
Symbol
Exchange
OTC US
Venture
As of 3:58 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

biosyent inc (RX) Snapshot

Open
C$5.69
Previous Close
C$5.73
Day High
C$5.72
Day Low
C$5.50
52 Week High
03/21/14 - C$6.00
52 Week Low
04/22/13 - C$1.08
Market Cap
78.0M
Average Volume 10 Days
17.2K
EPS TTM
C$0.15
Shares Outstanding
13.7M
EX-Date
--
P/E TM
38.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOSYENT INC (RX)

Related News

No related news articles were found.

biosyent inc (RX) Related Businessweek News

No Related Businessweek News Found

biosyent inc (RX) Details

BioSyent Inc., a life science company, engages in the marketing of pharmaceutical products in Canada. It is also involved in manufacturing and marketing non-chemical bio and health-friendly insecticides worldwide. The company markets FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; and FeraMAX Powder, an oral iron supplement. It also offers Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; endoscopies, proctoscopies, and rectoscopies; and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, BioSyent Inc. manufactures and markets Protect-It, a non-chemical, food-safe grain insecticide used as a preventative treatment against insect infestations in stored grains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 1947 and is headquartered in Toronto, Canada.

Founded in 1947

biosyent inc (RX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: C$154.1K
Chief Financial Officer and Vice President
Total Annual Compensation: C$112.0K
Compensation as of Fiscal Year 2012.

biosyent inc (RX) Key Developments

BioSyent Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

BioSyent Inc. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported Revenue was $2,142,835 against $1,327,953 a year ago. Net income before tax was $619,124 against $361,237 a year ago. Net income after tax was $555,544 against $503,432 a year ago. For the year, the company reported Revenue was $7,799,426 against $5,024,154 a year ago. Net income before tax was $2,452,840 against $1,399,122 a year ago. Net income after tax was $1,928,028 against $1,541,317 a year ago. Fully Diluted EPS was $0.13, Cash Generation in 2013 was $2,065,082 64% higher than 2012.

BioSyent Inc. Appoints Stephen Wilton to Board

The Board of Directors of BioSyent Inc. announced the appointment of Stephen Wilton to the company's Board. Wilton brings to BioSyent over 28 years of experience in the pharmaceutical industry. After working in medical sales and marketing positions at Eli Lilly Canada he joined AstraZeneca Canada where he enjoyed a long and varied career. After his 17 year career at AstraZeneca, Mr. Wilton worked as Vice President of Pharmacy Affairs for the Canadian Association of Chain Drug Stores representing the interests of owners and pharmacists in the Canadian healthcare system.

BioSyent Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013

BioSyent Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2013. For the quarter, the company's revenues were CAD 2,328,064 against CAD 1,575,598 a year ago. Profit before tax was CAD 808,789 against CAD 427,265 a year ago. Profit after tax was CAD 609,749 against CAD 427,265 a year ago. Basic EPS of CAD 0.05 and fully diluted EPS of CAD 0.04. For the nine months, the company's revenues were CAD 5,656,591 against CAD 3,696,201 a year ago. Profit before tax was CAD 1,833,716 against CAD 1,037,885 a year ago. Profit after tax was CAD 1,372,484 against CAD 1,037,885 a year ago. Basic earnings per share for nine months ending September 2013 of CAD 0.10 versus CAD 0.08 in prior year period.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RX:CN C$5.70 CAD -0.03

RX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RX.
View Industry Companies
 

Industry Analysis

RX

Industry Average

Valuation RX Industry Range
Price/Earnings 41.0x
Price/Sales 9.7x
Price/Book 15.4x
Price/Cash Flow 39.0x
TEV/Sales 9.1x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSYENT INC, please visit www.biosyent.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.